Y-mAbs Therapeutics Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics or view top-rated stocks.

Wall Street analysts have given Y-mAbs Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Y-mAbs Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Y-mAbs Therapeutics.

Y-mAbs Therapeutics will be holding an earnings conference call on Friday, August 6th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) issued its earnings results on Thursday, May, 6th. The company reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.61 by $0.14. The firm had revenue of $5.38 million for the quarter, compared to analyst estimates of $35.67 million.
View Y-mAbs Therapeutics' earnings history.

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, YMAB shares have increased by 45.3% and is now trading at $33.40.
View which stocks have been most impacted by COVID-19.

7 equities research analysts have issued 1 year price targets for Y-mAbs Therapeutics' stock. Their forecasts range from $45.00 to $68.00. On average, they expect Y-mAbs Therapeutics' stock price to reach $55.14 in the next twelve months. This suggests a possible upside of 65.1% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Y-mAbs Therapeutics include Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Apellis Pharmaceuticals (APLS), Arvinas (ARVN), Schrödinger (SDGR), Reata Pharmaceuticals (RETA), Hypera (HYPMY), Allakos (ALLK), Alkermes (ALKS), Galapagos (GLPG), TG Therapeutics (TGTX), Arena Pharmaceuticals (ARNA) and Lyell Immunopharma (LYEL).
View all of YMAB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Y-mAbs Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (3.10%), Rice Hall James & Associates LLC (0.22%) and Hillsdale Investment Management Inc. (0.06%). Company insiders that own Y-mAbs Therapeutics stock include Biotech Aps Wg, Bo Kruse, David N Gill, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends for Y-mAbs Therapeutics.

YMAB stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Pedro Claus Juan Moller-San, and Thomas Gad.
View insider buying and selling activity for Y-mAbs Therapeutics or view top insider-selling stocks.

YMAB stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., and Hillsdale Investment Management Inc.. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include James Healy, Pedro Claus Juan Moller-San, and Vignesh Rajah.
View insider buying and selling activity for Y-mAbs Therapeutics or or view top insider-buying stocks.

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of YMAB stock can currently be purchased for approximately $33.40.

Y-mAbs Therapeutics has a market capitalization of $1.46 billion and generates $20.75 million in revenue each year. The company earns $-119,340,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis.

Y-mAbs Therapeutics employs 125 workers across the globe.

The official website for Y-mAbs Therapeutics is www.ymabs.com.

Y-mAbs Therapeutics is headquartered at 230 Park Avenue Suite 3350, NEW YORK NY, 10169.

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]